RAGE受容体を調節するための化合物

Japanese Patent JP2004519416

A

This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, ²-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction and tumor invasion and metastasis.

Mali, Adnan
Gopalathwamy, Ramesh
Abort, Oak
Isong, Christopher
Patron, Andrew

JP2002500825A

July 02, 2004

May 25, 2001

Click for automatic bibliography generation  

TRANSTECH PHARMA,INC.

A61K31/17; A61K31/18; A61K31/198; A61K31/245; A61K31/27; A61K31/325; A61K31/34; A61K31/341; A61P3/10; A61P9/10; A61P13/12; A61P15/10; A61P25/28; A61P27/02; A61P29/00; A61P35/00; A61P35/04; A61P43/00; C07C231/12; C07C231/14; C07C237/12; C07C237/20; C07C237/22; C07C269/06; C07C271/18; C07C271/22; C07C271/28; C07C273/18; C07C275/24; C07C277/08; C07C279/14; C07C303/38; C07C311/04; C07C311/06; C07C311/17; C07C311/19; C07D307/42; (IPC1-7): C07C237/12; A61K31/198; A61K31/245; A61K31/27; A61K31/341; A61P3/10; A61P9/10; A61P13/12; A61P15/10; A61P25/28; A61P27/02; A61P29/00; A61P35/00; A61P35/04; A61P43/00; C07C231/12; C07C231/14; C07C269/06; C07C271/28; C07C273/18; C07C275/24; C07C277/08; C07C279/14; C07C303/38; C07C311/06; C07C311/19; C07D307/42

Hiroyuki Okamoto

Previous Patent: 組換えヒトＣＬＮ２タンパク質およびその生成方法ならびに使用

Next Patent: 培地用ペプチド